Are GLP-1 drugs affecting patients’ nails?

Clinical takeaway: Ask patients taking GLP-1 receptor agonists about nail changes, particularly nail detachment and discoloration, and consider dermatologic evaluation when symptoms arise. These findings do not establish causality and should not prompt patients to discontinue effective therapy on their own.

GLP-1 receptor agonists are widely used for obesity and type 2 diabetes, yet their effects on nail health have received little formal study. Presented at the EADV Congress 2026 and not yet peer reviewed, these findings provide some of the first controlled data examining potential nail-related adverse effects associated with this drug class.

In the first controlled study to examine nail health among GLP-1 users, researchers compared 575 people taking a GLP-1 receptor agonist with 1,329 individuals with obesity and/or type 2 diabetes who had never used the drugs. Overall, 66% of GLP-1 users reported at least one nail disorder versus 53% of controls.

Nail detachment was reported by 39% of GLP-1 users compared with 9% of controls, making it more than four times as common among those receiving the medications. Nail discoloration was also substantially more frequent, affecting 46% of users versus 17% of controls. Notably, the differences persisted when analyses were limited to participants who had lost weight, suggesting that weight loss alone may not fully explain the findings.

The investigators cautioned that the cross-sectional, patient-reported study cannot prove that GLP-1 therapies caused the nail abnormalities. About half of users reported nail problems that predated treatment, and adjustment for dermatologic conditions and nutritional deficiencies weakened some associations. However, nail detachment and discoloration remained roughly two to three times more common among GLP-1 users after adjustment.

A companion analysis also found higher rates of hair loss, reduced hair density, and scalp inflammation among GLP-1 users, raising the possibility that factors beyond weight loss may contribute to these dermatologic changes.

Researchers next plan prospective studies that follow patients from treatment initiation, with standardized dermatologic assessments and biologic monitoring to better determine when these changes develop, why they occur, and whether they are reversible.

“These changes are frequent, usually benign, and are not a reason to stop an effective treatment on one’s own initiative,” said study author Dr Bruno Halioua. “Anyone who notices hair shedding, an itchy or red scalp or nail changes should mention it to their doctor rather than discontinue therapy.”

Source: Taïeb C, et al. (2026 Oct 1) EADV Congress 2026. Nail detachment over four times more common among GLP-1 users, first controlled study finds